


PHARMACEUTICAL 2017

Teligent Inc. Rank 165 of 292





PHARMACEUTICAL 2017

Teligent Inc. Rank 165 of 292

The relative strengths and weaknesses of Teligent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Teligent Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Teligent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 52% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	103,296
Cost of Goods Sold	0
Intangible Assets	52,911
Liabilities, Current	14,963
Liabilities, Non-Current	0
Other Assets	804
Other Compr. Net Income	-1,475
Other Expenses	32,481
Other Liabilities	111,596
Other Net Income	-14,240
Other Revenues	66,881
Property and Equipment	26,215
Research and Development	17,140
Selling, General and Administrative Expense	15,005

Output Variable	Value in 1000 USD
Assets	183,226
Liabilities	126,559
Expenses	64,626
Revenues	66,881
Stockholders Equity	56,667
Net Income	-11,985
Comprehensive Net Income	-12,722
Economic Capital Ratio	55%

